PAK3 and prostate adenocarcinoma: In this study, using publicly available transcriptome expression data from the TCGA, we evaluated the modifications in the hub proteins, such as polo like kinase 1 (PLK1), cell division cycle 20 (CDC20), caveolin 1 (CAV1), camodulin 1 (CALM1), and p21 activated kinase 3 (PAK3), in relation to their clinical significance and determined which categories of immune cells have been associated with poorly differentiated prostate adenocarcinomas, as indicated by high Gleason scores.